SCHEMBL1899328

SCHEMBL1899328

CCCCN(CC)c1ccc(OC(F)(F)F)cc1CN(Cc1cc(C#N)cc(C(F)(F)F)c1)C(=O)OC

nearest known ligand 0.45

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CETP P11597 17/20 0.45
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
SERPINE1 P05121 1/20 0.37
CRHR1 P34998 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5671071 0.93 NR1H2 (0.41) CETPNR1H2NR1H3SERPINE1CRHR1
SCHEMBL1899458 0.88 CETP (0.46) CETP
SCHEMBL1901787 0.86 CETP (0.46) CETPNR1H2NR1H3SERPINE1
SCHEMBL1901560 0.84 CETP (0.43) CETP
SCHEMBL1901098 0.83 CETP (0.53) CETPSERPINE1
SCHEMBL5148374 0.81 SERPINE1 (0.39) CETPNR1H2NR1H3SERPINE1CRHR1
SCHEMBL5670517 0.80 KCNH2 (0.38) CETPNR1H2NR1H3
SCHEMBL5671189 0.79 CYP3A4 (0.43) CETPNR1H2NR1H3SERPINE1CRHR1
SCHEMBL5669136 0.76 CETP (0.34) CETP
SCHEMBL1897140 0.76 CETP (0.62) CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054839-A1 Method of inhibiting remnant lipoprotein production JAPAN TOBACCO INC. (JP) 2007-03-08 US claimed
US-20060270705-A1 Method for inhibiting lipid absorption and lipid absorption inhibitor JAPAN TOBACCO INC. (JP) 2006-11-30 US claimed
US-20110189210-A1 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2011-08-04 US disclosed
EP-2319509-A1 Method of Inhibiting remnant lipoprotein production Japan Tobacco, Inc. (JP) 2011-05-11 EP disclosed
EP-2316447-A1 Method of inhibiting remnant lipoprotein production Japan Tobacco, Inc. (JP) 2011-05-04 EP disclosed
US-20070054839-A1 Method of inhibiting remnant lipoprotein production JAPAN TOBACCO INC. (JP) 2007-03-08 US disclosed
US-20060270705-A1 Method for inhibiting lipid absorption and lipid absorption inhibitor JAPAN TOBACCO INC. (JP) 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054839-A1 Method of inhibiting remnant lipoprotein production CETP, PCSK9, LIPA CETP 1/4885NR1H2 30/4885NR1H3 33/4885
US-20110189210-A1 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION CETP, PCSK9, LIPA CETP 1/4885NR1H2 30/4885NR1H3 33/4885
US-20060270705-A1 Method for inhibiting lipid absorption and lipid absorption inhibitor CETP, SI, LIPC CETP 1/4885NR1H2 82/4885NR1H3 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.